There are 768 papers on left ventricular ejection fraction in aging research: 102 trials and 523 observational studies in people, 42 in animals, 69 reviews.
768 papers study it336 more mention it130 findings
316 new papers in 30 daysSee all 1,104 papers on left ventricular ejection fraction
“A ≥1 SD increase in PWV was associated with a mean LVEF decline of 2.7% (95% CI -4.65 to -0.81, p=0.006).”
- Human trial102
- Humans523
- Animals42
- In silico9
Interventions
41SGLT2 inhibitors
upin humans7no changein humans1+0.6% per year
8 studies
SGLT2 inhibitors
upin humans7no changein humans1+0.6% per year
SGLT2 inhibitors increase left ventricular ejection fraction in humans (on top of GDMT versus placebo) (MD +3.59%; 95% CI 1.12–6.06; p=0.004).
“and increase in LVEF (MD +3.59%; 95% CI 1.12–6.06; p=0.004)”
Human trialon top of GDMT versus placebo
ESC Congress 2026 abstract
SGLT2 inhibitors increase left ventricular ejection fraction in humans (post-ACS diabetic patients, SGLT2i group vs control, at 3 months) (49.9% to 51.9%).
“with significant increases in LVEF (49.9% to 51.9%, p<0.001)”
Human trialpost-ACS diabetic patients, SGLT2i group vs control, at 3 monthsleft ventricle3 monthsn = 25
ESC Congress 2026 abstract
SGLT2 inhibitors increase left ventricular ejection fraction in patients with diabetes mellitus, hypertension and coronary artery disease.
“The left ventricular ejection fractions, quality of life scores and overall clinical response rates were higher (P<0.05).”
Human trialin patients with diabetes mellitus, hypertension and coronary artery diseaseheart
Pakistan journal of pharmaceutical sciences
SGLT2 inhibitors increase left ventricular ejection fraction in patients with type 2 diabetes mellitus and coronary artery disease (+ 4.6% vs − 1.0%, p ≤ 0.01).
“increased LV ejection fraction (+ 4.6% vs − 1.0%) (all p ≤ 0.01)”
Human trialin patients with type 2 diabetes mellitus and coronary artery disease6 monthsn = 302
Research SquarePreprint
SGLT2 inhibitors were not clearly linked with left ventricular ejection fraction in humans (type 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparison).
“LVEF remained stable”
Humanstype 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparisonheartempagliflozin 10 mg/day or dapagliflozin 10 mg/day6 monthsn = 51
Research SquarePreprint
SGLT2 inhibitors are linked with better left ventricular ejection fraction in patients with type 2 diabetes and cancer receiving antineoplastic therapy.
“Echocardiography showed improved left ventricular ejection fraction (LVEF) and reduced left ventricular end-diastolic diameter (LVID)/left atrial (LA) dimensions (all p < .001).”
Humansin patients with type 2 diabetes and cancer receiving antineoplastic therapyleft ventricle
International journal of cancer
SGLT2 inhibitors are linked with better left ventricular ejection fraction in patients with Fabry disease on Fabry-specific therapy (+0.6% per year).
“a slight but significant improvement of LVEF by 0.6% per year (p = 0.0319) was observed, which was more prominent in males with a reduced LVEF (< 50%) at baseline”
Humansin patients with Fabry disease on Fabry-specific therapyheart12 monthsn = 48
Impact of SGLT2 inhibitors in patients with Fabry disease
Clinical research in cardiology : official journal of the German Cardiac Society
SGLT2 inhibitors increase left ventricular ejection fraction in humans (heart failure; compared with placebo) (MD +1.90; 95% CI 0.63 to 3.17).
“SGLT2 inhibitors significantly improved LVEF (MD +1.90; 95% CI 0.63 to 3.17; P = 0.003)”
Reviewheart failure; compared with placeboheartn = 868
AHA Scientific Sessions 2026 abstract
Dapagliflozin
upin humans6upin mice1
7 studies
Dapagliflozin
upin humans6upin mice1
Dapagliflozin increases left ventricular ejection fraction in humans (patients with sepsis receiving standardized treatment) (Median 60.0% versus 55.0% in controls).
“On the 5th day of treatment, the median LVEF was significantly higher in the intervention group”
Human trialpatients with sepsis receiving standardized treatmentheart10 mg5 days
Zhonghua nei ke za zhi
Dapagliflozin increases left ventricular ejection fraction in humans (non-diabetic patients with AMI after PCI) (52.24% vs 47.66%).
“Group I demonstrated superior cardiac improvement: higher LVEF (52.24 % vs. 47.66 %; p = 0.025)”
Human trialnon-diabetic patients with AMI after PCIleft ventricle6 months
Journal of the Saudi Heart Association
Dapagliflozin improves left ventricular ejection fraction in patients with HFrEF combined with T2DM.
“After treatment, the pancreatic beta-cell function index, left ventricular ejection fraction, and glomerular filtration rate of patients in the study group were significantly higher than control group (P < 0.001)”
Human trialin patients with HFrEF combined with T2DM
Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety
World journal of diabetes
Dapagliflozin is linked with better left ventricular ejection fraction in HFrEF and HFpEF patients (+3.2% in HFrEF, +0.9% in HFpEF).
“LVEF increased in HFrEF (+3.2%) and HFpEF (+0.9%).”
Humansin HFrEF and HFpEF patients3 months
Dapagliflozin and ventricular repolarization across heart failure phenotypes
Current medical research and opinion
Dapagliflozin is linked with higher left ventricular ejection fraction in humans (+5.98 ± 7.39% points).
“mean LVEF increased from baseline to follow-up by 5.98 ± 7.39% points among 213 patients with paired LVEF data (paired p < 0.001)”
Humansn = 213
Scientific reports
Dapagliflozin is linked with higher left ventricular ejection fraction in humans (2DE: 36.6±8.8 vs. 34.5±7.7%; 3DE: 37.4±8.7 vs. 34.4±7.9%; p < 0.001).
“After 6MFU, left ventricular (LV) end-diastolic and end-systolic volumes reduced, and LVEF increased”
HumansHeart failure with reduced ejection fraction on guideline-directed therapy; before-and-after comparisonheart10 mg daily6 monthsn = 75
Echocardiography (Mount Kisco, N.Y.)
Dapagliflozin improves left ventricular ejection fraction in mice (experimental myocardial infarction).
“Consistently, echocardiography showed improved left ventricular ejection fraction and reduced ventricular dilation after MI.”
Animalsexperimental myocardial infarctionheart
ESC Congress 2026 abstract
Exercise
upin humans2no changein humans1upin mice1
4 studies
Exercise
upin humans2no changein humans1upin mice1
Exercise improves left ventricular ejection fraction in humans (chronic heart failure).
“LVEF in the rehabilitation group was higher than that in the control group, and LVESV and LVEDV were both lower than those in the control group (P<0.05)”
Human trialchronic heart failure3 monthsn = 92
Chinese Health Care
Exercise improves left ventricular ejection fraction in humans (chronic heart failure).
“The experimental group demonstrated significant improvements in the 6-minute walk test, left ventricular ejection fraction, and quality of life compared to the control group (P < 0.05).”
Human trialchronic heart failure12 weeksn = 80
Impact of Resilience-Based Exercise on Quality of Life and Cardiac Function in Elderly CHF Patients
GSA 2025 abstract
Exercise increases left ventricular ejection fraction in doxorubicin-treated mice.
“Echocardiography revealed restored systolic function with elevated left ventricular ejection fraction (LVEF) and fractional shortening (LVFS).”
Animalsin doxorubicin-treated miceheartmales
Research SquarePreprint
Exercise showed no clear effect on left ventricular ejection fraction in atrial fibrillation patients.
“it does not significantly improve ejection fraction or heart rate”
Reviewin atrial fibrillation patientsn = 1,251
Clinics (Sao Paulo, Brazil)
Empagliflozin
no changein humans1upin pigs1
2 studies
Empagliflozin
no changein humans1upin pigs1
Empagliflozin showed no clear effect on left ventricular ejection fraction in humans (older adults with overweight and at least one heart failure risk factor).
“No significant differences were observed for LV volumes or ejection fraction.”
Human trialolder adults with overweight and at least one heart failure risk factorleft ventricle10 mg daily180 daysn = 165
Journal of cardiac failure
Empagliflozin increases left ventricular ejection fraction in pigs (pacemaker-induced premature ventricular contractions) (50 ± 10.2% with empagliflozin versus 34 ± 4.35% in the PVC group).
“whereas EMPA attenuated LV dysfunction (50 ± 10.2, p=0.059)”
Animalspacemaker-induced premature ventricular contractionsleft ventricle0.5 mg/kg/day12 weeks
AHA Scientific Sessions 2026 abstract
Essential amino acids
upin humans1
1 study
Essential amino acids
upin humans1
Essential amino acids improve left ventricular ejection fraction in humans (from 34.3 ± 1.5 to 35.80 ± 1.7%).
“Of particular interest, after six months’ follow-up, there was a significant improvement in LVEF (from 34.3 ± 1.5 to 35.80 ± 1.7%, p < 0.001) and GLS (−8.5 ± 1.07 vs. −11.9 ± 1.23, p < 0.001).”
Human trial6 monthsn = 60
International journal of molecular sciences
Essential amino acids improve left ventricular ejection fraction in humans (chronic heart failure with reduced ejection fraction and sarcopenia).
“after 6 months' follow-up, there was a significant improvement in LVEF and global longitudinal strain (GLS).”
Human trialchronic heart failure with reduced ejection fraction and sarcopenia6 monthsn = 60
International journal of molecular sciences
Exercise rehabilitation based on medical care-family integration
upin humans1
1 study
Exercise rehabilitation based on medical care-family integration
upin humans1
Exercise rehabilitation based on medical care-family integration increases left ventricular ejection fraction in humans.
“After intervention, the 6 MWD and LVEF were higher, while the NT-proBNP level and LVEDD were significantly lower in the exercise rehabilitation group compared to the conventional rehabilitation group (P < 0.05).”
Human trial3 monthsn = 118
World journal of psychiatry
Exercise rehabilitation based on medical care-family integration increases left ventricular ejection fraction in older patients with chronic heart failure and psychological problems (P < 0.05).
“LVEF values were higher compared to the conventional rehabilitation group (P < 0.05).”
Human trialin older patients with chronic heart failure and psychological problemsn = 118
World journal of psychiatry
More on Exercise rehabilitation based on medical care-family integration
Home-based cardiac telerehabilitation
upin humans1
1 study
Home-based cardiac telerehabilitation
upin humans1
Home-based cardiac telerehabilitation increases left ventricular ejection fraction in humans (at 6 months) (7.7% versus 3.8%).
“There was a significant improvement in the cardiac function in intervention group compared with control group after 6 months.”
Human trialat 6 months6-month periodn = 81
Medicine
Home-based cardiac telerehabilitation increases left ventricular ejection fraction in humans (heart failure with left ventricular ejection fraction <40%) (+7.7% absolute, +25.6% relative, P < .05, 95% CI -7.8 to -0.5).
“Left ventricular ejection fraction increased by 7.7%, which corresponds to 25.6% in relative terms (P < .05, 95% confidence interval -7.8 to -0.5).”
Human trialheart failure with left ventricular ejection fraction <40%6-monthn = 40
Medicine
Multidisciplinary cardiac case conference
upin humans1
1 study
Multidisciplinary cardiac case conference
upin humans1
Multidisciplinary cardiac case conference is linked with higher left ventricular ejection fraction in humans (heart failure with reduced ejection fraction) (+12.1±10.8%).
“Mean LVEF improved +12.1±10.8% (p<0.001)”
Humansheart failure with reduced ejection fractionleft ventriclen = 89
ESC Congress 2026 abstract
Sleeve gastrectomy
upin humans1
1 study
Sleeve gastrectomy
upin humans1
Sleeve gastrectomy increases left ventricular ejection fraction in humans (patients with obesity; compared with control) (MD 16.50%; 95% CI 10.41–22.59).
“SG significantly increased LVEF (MD 16.50%; 95% CI 10.41–22.59) and reduced LV end-diastolic diameter (MD −5.20 mm; 95% CI −8.67 to −1.73).”
Reviewpatients with obesity; compared with controlheart1 year
ESC Congress 2026 abstract
Cardio-oncology disease management program
upin humans1
1 study
Cardio-oncology disease management program
upin humans1
Cardio-oncology disease management program increases left ventricular ejection fraction in humans (Change 4.26±5.66% versus 1.13±6.94%; p=0.001).
“CO-DMP was associated with significant between group differences in myocardial function, including greater improvements in LVEF (4.26±5.66% vs 1.13±6.94%; p=0.001)”
Human triallong-term cancer survivors with subclinical/Stage B heart failure; compared with usual careheart6 monthsn = 144
ESC Congress 2026 abstract
Luseogliflozin
upin humans1
1 study
Luseogliflozin
upin humans1
Luseogliflozin improves left ventricular ejection fraction in humans (type 2 diabetes, per-protocol analysis) (72.7 ± 4.9 vs 75.7 ± 4.6, p = 0.033; interaction p = 0.041).
“Luseogliflozin significantly improved LVEF (72.7 ± 4.9 vs 75.7 ± 4.6 p = 0.033”
Human trialtype 2 diabetes, per-protocol analysisheartweek 24n = 33
ADA Scientific Sessions 2026 abstract
Psychological support
upin humans1
1 study
Psychological support
upin humans1
Psychological support improves left ventricular ejection fraction in patients with chronic heart disease (56.2 ± 6.1% vs. 54.1 ± 6.3%).
“Cardiac imaging also improved, with higher left ventricular ejection fraction (56.2 ± 6.1% vs. 54.1 ± 6.3%)”
Human trialin patients with chronic heart disease12 monthsn = 200
Journal of cardiothoracic surgery
Glycemic optimization
upin humans1
1 study
Glycemic optimization
upin humans1
Glycemic optimization increases left ventricular ejection fraction in humans (newly diagnosed type 2 diabetes) (59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01).
“CMR evaluation revealed increases in left ventricle (LV) ejection fraction (59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01)”
Human trialnewly diagnosed type 2 diabetes12 monthsn = 20
Cardiovascular diabetology
Augmented reality-based sensory interaction device
upin humans1
1 study
Augmented reality-based sensory interaction device
upin humans1
Augmented reality-based sensory interaction device improves left ventricular ejection fraction in humans (chronic heart failure) (54.11% vs. 51.85%).
“Post-intervention analysis revealed significant improvements in the intervention group across several parameters, including left ventricular ejection fraction (LVEF: 54.11% vs. 51.85%, P < 0.001)”
Human trialchronic heart failurefour-weekn = 200
BMC cardiovascular disorders
Running
downin humans1
1 study
Running
downin humans1
Running decreases left ventricular ejection fraction in humans (immediately post-race).
“Immediately post-race, LVEF decreased slightly but remained within the normal range”
Human trialimmediately post-racen = 105
International journal of cardiology. Heart & vasculature
All 41Fewer
Effects
6Physical function
no changein humans1
1 study
Physical function
no changein humans1
Left ventricular ejection fraction was not clearly linked with physical function in patients with cardiovascular disease.
“Left ventricular ejection fraction had no significant association with functional outcomes.”
Humansin patients with cardiovascular diseasen = 61
KOREAN ACADEMY OF CARDIORESPIRATORY PHYSICAL THERAPY
Sarcopenia
no changein silico1
1 study
Sarcopenia
no changein silico1
Left ventricular ejection fraction showed no clear effect on sarcopenia in silico.
“there was no evidence of a causal effect of LVEF on any of the 3 sarcopenia-related traits.”
In silico
Interdisciplinary Nursing Research
Kansas City Cardiomyopathy Questionnaire-12
no changein humans1
1 study
Kansas City Cardiomyopathy Questionnaire-12
no changein humans1
Left ventricular ejection fraction was not clearly linked with Kansas City Cardiomyopathy Questionnaire-12 in humans (chronic heart failure).
“Left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide showed no significant association with health status.”
Humanschronic heart failuren = 150
medRxivPreprint
NfL
no changein humans1
1 study
NfL
no changein humans1
Left ventricular ejection fraction was not clearly linked with NfL in humans.
“nor were echocardiographic variables associated with NfL or GFAP”
Humansn = 962
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Kansas City Cardiomyopathy Questionnaire
no changein humans1
1 study
Kansas City Cardiomyopathy Questionnaire
no changein humans1
Left ventricular ejection fraction was not clearly linked with Kansas City Cardiomyopathy Questionnaire in humans (transthyretin cardiac amyloidosis).
“Gender, ATTR-CA type, phenotype, and LVEF were not associated with health status.”
Humanstransthyretin cardiac amyloidosisn = 138
Aging clinical and experimental research
Number of hospital readmissions
downin humans1
1 study
Number of hospital readmissions
downin humans1
Left ventricular ejection fraction is linked with lower number of hospital readmissions in humans (acute heart failure) (standardized regression coefficient -0.32).
“LVEF (-0.32), and degree of frailty (0.29) were extracted as significant factors.”
Humansacute heart failure
Frailty in elderly patients with acute heart failure increases readmission
Heart & lung : the journal of critical care
Upstream
9Hypertensive disorders of pregnancy
no changein humans1
1 study
Hypertensive disorders of pregnancy
no changein humans1
Hypertensive disorders of pregnancy was not clearly linked with left ventricular ejection fraction in humans After adjustment for cardiovascular risk factors (β = 0.76, 95% CI -0.38 to 1.90).
“left ventricular ejection fraction (β = 0.76, 95% CI -0.38 to 1.90, p = 0.193)”
HumansAfter adjustment for cardiovascular risk factorsheartfemales
Frontiers in cardiovascular medicine
Preeclampsia
no changein humans1
1 study
Preeclampsia
no changein humans1
Preeclampsia showed no clear effect on left ventricular ejection fraction in humans (Preeclampsia compared with controls).
“Left ventricular ejection fraction and right ventricular function remained similar in the preeclampsia and control groups throughout.”
ReviewPreeclampsia compared with controlsheartfemales
Cardiac Structure and Function in Women After Preeclampsia: A Systematic Review and Meta-Analysis
JACC. Heart failure
Lipoprotein
downin humans1
1 study
Lipoprotein
downin humans1
Lipoprotein is linked with lower left ventricular ejection fraction in Hispanic subjects (β, -0.75 [95% CI, -1.34 to -0.17]).
“Each 1-SD increase in log-transformed Lp(a) was associated with an increase in left ventricular end-systolic volume index (β, 0.60 [95% CI, 0.02-1.18]), and left atrial minimum volume index (β, 0.81 [95% CI, 0.09-1.52]), and a decline in left ventricular ejection fraction (β, -0.75 [95% CI, -1.34 to -0.17]), and total left atrial emptying fraction (β, -1.17 [95% CI, -2.09 to -0.24]) in Hispanic subjects over a decade.”
Humansin Hispanic subjects10 yearsn = 2,366
Circulation. Population health and outcomes
Automated deep learning analysis of echocardiography
upin humans1
1 study
Automated deep learning analysis of echocardiography
upin humans1
automated deep learning analysis of echocardiography is linked with higher left ventricular ejection fraction in humans (hospitalized patients) (mean difference 5.8%, P < 0.001).
“AI-derived LVEF values were significantly higher than human estimates (mean difference 5.8%, P < 0.001).”
Humanshospitalized patientsn = 731
European heart journal. Digital health
Age
no changein humans1
1 study
Age
no changein humans1
Age was not clearly linked with left ventricular ejection fraction in humans (healthy).
“LVEF was similar across age groups.”
Humanshealthyheart
Journal of cardiovascular imaging
Sarcopenia
downin humans1
1 study
Sarcopenia
downin humans1
Sarcopenia is linked with lower left ventricular ejection fraction in elderly patients with coronary heart disease (p < 0.05).
“The sarcopenia group showed lower cardiac output and left ventricular ejection fraction levels than the non-sarcopenia group”
Humansin elderly patients with coronary heart diseasen = 318
BMC cardiovascular disorders
Female sex
upin humans1
1 study
Female sex
upin humans1
Female sex is linked with higher left ventricular ejection fraction in humans (older BASE-II subsample).
“Echocardiography revealed that left ventricular ejection fraction was higher in women than in men”
Humansolder BASE-II subsamplen = 1,100
BMJ open
Atrial fibrillation
downin humans1
1 study
Atrial fibrillation
downin humans1
Atrial fibrillation is linked with lower left ventricular ejection fraction in hypertensive patients (p < 0.05).
“Left Ventricular Ejection Fraction (LVEF) were significantly decreased”
Humansin hypertensive patientsn = 155
Brain sciences
Progeria
upin humans1
1 study
Progeria
upin humans1
Progeria is linked with higher left ventricular ejection fraction in humans (compared to older healthy volunteers).
“Children with HGPS had higher left ventricular ejection fraction (LVEF) and global longitudinal strain, when compared to older healthy volunteers (P < 0.05)”
Humanscompared to older healthy volunteersleft ventriclen = 7
BioMed research international
Associations
44Mortality
upin humans4downin humans4HR 0.66–2.28
8 studies
Mortality
upin humans4downin humans4HR 0.66–2.28
Left ventricular ejection fraction predicts mortality in humans (Heart failure; reduced LVEF; multivariable model) (HR 1.33, 95% CI 1.27–1.38).
“reduced LVEF (HR 1.33, 95% CI 1.27–1.38)”
HumansHeart failure; reduced LVEF; multivariable model202453.6% womensn = 149,703
Total illness burden strongly predicts heart failure death
ESC Congress 2026 abstract
Left ventricular ejection fraction is associated with mortality in humans (non-obstructive coronary artery disease) (HR 0.978; 95% CI: 0.968–0.989).
“LVEF (HR 0.978; 95% CI: 0.968–0.989), and LVMI (HR 1.008; 95% CI: 1.003–1.012) were associated with mortality.”
Humansnon-obstructive coronary artery diseasemales
ESC Congress 2026 abstract
Left ventricular ejection fraction predicts mortality in humans (multivariable analysis in STEMI patients after primary PCI) (OR 2.71, p=0.029).
“post-PCI LVEF <40% (OR 2.71; p=0.029)”
Humansmultivariable analysis in STEMI patients after primary PCIn = 585
ESC Congress 2026 abstract
Left ventricular ejection fraction predicts mortality in humans (acute heart failure) (HR 1.16, P<0.001).
“All 3 indices predicted mortality (per 10% decrease in LVEF: hazard ratio (HR) 1.16”
Humansacute heart failuremedian follow-up of 32.6 monthsn = 3,688
Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myocardium
Journal of the American Heart Association
Left ventricular ejection fraction predicts mortality in humans (LVEF <50%: HR 2.28, 95% CI 1.78–2.93; P ≤ .0001).
“left ventricular ejection fraction (LVEF) <50% (2.28 [1.78-2.93], P ≤ .0001)”
HumansLeft ventricular ejection fraction <50%; after minimally invasive mitral valve repair; multivariable modeln = 501
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Left ventricular ejection fraction is linked with a lower risk of mortality in humans (HR 0.66, P < 0.001).
“(5% increase of left ventricular ejection fraction: HR 0.66; P < 0.001) were significantly associated with outcome.”
Humans5% increase6 monthsn = 69
Short- and long-term survival in patients over 90 years old undergoing pacemaker implantation
Journal of cardiovascular medicine (Hagerstown, Md.)
Left ventricular ejection fraction is associated with mortality in octogenarian population.
“left ventricular ejection fraction (P=0.003), serum albumin (P=0.020), C-Reactive protein (P=0.020) and renin-angiotensin system inhibitors at hospital discharge were negatively correlated with mortality”
Humansin octogenarian populationheart1-year follow-upn = 170
Journal de medecine vasculaire
Left ventricular ejection fraction predicts mortality in humans (Ambulatory patients with heart failure) (OR 0.93, CI 0.86–0.99; p = 0.05).
“left ventricular ejection fraction (OR 0.93, CI 0.86-0.99, p = 0.05), and peak VO2 (OR 0.78, CI 0.65-0.94, p = 0.008) were predictors of death.”
HumansAmbulatory patients with heart failureheartMean follow-up of 21 monthsn = 130
Wiener klinische Wochenschrift
SGLT2 inhibitors
upin humans2+51% patients showed improvement
2 studies
SGLT2 inhibitors
upin humans2+51% patients showed improvement
SGLT2 inhibitors are associated with left ventricular ejection fraction in humans (heart failure; uncontrolled comparison with baseline) (Median LVEF 28.8% at baseline versus 31.6% at 6 months; paired LVEDV and LVESV changes −13.0% and −16.3%).
“SGLT2i initiation was followed by modest LV volume reduction and a small LVEF increase.”
Humansheart failure; uncontrolled comparison with baselineleft ventricle6 monthsn = 101
Journal of clinical medicine
SGLT2 inhibitors are associated with left ventricular ejection fraction in humans (51.4% of patients showed improvement).
“More than half (51.4%) showed LVEF improvement”
Humansheart
Frontiers in cardiovascular medicine
Female sex
upin humans2
2 studies
Female sex
upin humans2
Female sex is associated with left ventricular ejection fraction in humans (healthy) (63.7% vs 61.9%).
“Women had higher mean LVEF (63.7%) than men (61.9%), with corresponding lower normal limits of 52.7% and 51.7%, respectively.”
Humanshealthyheart
Journal of cardiovascular imaging
female sex is associated with left ventricular ejection fraction in humans (centenarians) (58.4 ± 9.8 vs 51.6 ± 14.6%).
“females vs males, 58.4 ± 9.8 vs 51.6 ± 14.6%, p = 0.01”
Humanscentenariansheartn = 100
Echocardiographic Features of Longevity: A Cross-Sectional Study of Centenarians
Cureus
Frailty
downin humans2
2 studies
Frailty
downin humans2
Left ventricular ejection fraction is linked with a lower risk of frailty in humans (hospitalized patients with chronic heart failure).
“albumin and LVEF were protective factors.”
Humanshospitalized patients with chronic heart failuren = 256
Journal of clinical nursing
Left ventricular ejection fraction is associated with frailty in chronic heart failure.
“Conversely, higher albumin, hemoglobin, and left ventricular ejection fraction (LVEF) levels were negatively associated with frailty.”
Reviewin chronic heart failure
Reviews in cardiovascular medicine
Activities of Daily Living score
upin humans1
1 study
Activities of Daily Living score
upin humans1
Left ventricular ejection fraction is associated with activities of Daily Living score in humans (0.69-point higher ADL score per 10% higher LVEF (95% CI 0.16–1.22; q = 0.032)).
“each 10% higher LVEF was associated with a 0.69-point higher ADL score (95% CI, 0.16–1.22; q = 0.032)”
HumansHospitalized patients with atrial fibrillation; adjusted for age and previous ischemic stroke51.8% womensn = 83
Biomedicines
Non-response to SGLT2 inhibitors
upin humans1OR 1.89
1 study
Non-response to SGLT2 inhibitors
upin humans1OR 1.89
Left ventricular ejection fraction predicts non-response to SGLT2 inhibitors in humans (heart failure with reduced ejection fraction; baseline LVEF ≤25%) (OR 1.89, 95% CI 1.53-2.34 for baseline LVEF ≤25%).
“baseline LVEF ≤25% (OR 1.89, 95% CI 1.53-2.34)”
Humansheart failure with reduced ejection fraction; baseline LVEF ≤25%6-12 monthsn = 4,723
AHA Scientific Sessions 2026 abstract
Heart rate variability
upin humans1OR 1.42
1 study
Heart rate variability
upin humans1OR 1.42
Heart rate variability predicts left ventricular ejection fraction in humans (Heart failure; SDNN >35 ms) (OR 1.42 for LVEF improvement, 95% CI 1.28 to 1.57).
“Higher HRV (SDNN >35 ms) predicted LVEF improvement (OR 1.42, 95% CI 1.28 to 1.57; p<0.001).”
HumansHeart failure; SDNN >35 msheartMedian 8.2 months54% malesn = 8,000
AHA Scientific Sessions 2026 abstract
Major adverse cardiovascular events
downin humans1OR 0.96
1 study
Major adverse cardiovascular events
downin humans1OR 0.96
Left ventricular ejection fraction is associated with major adverse cardiovascular events in humans (Atrial fibrillation undergoing index pulmonary vein isolation) (OR 0.96, 95% CI 0.94–0.98; p<0.001).
“LVEF before index PVI (Odds Ratio (95%CI) 0.96 (0.94; 0.98), p<0.001) and regular sports (0.49 (0.29; 0.81), p<0.001) were strongly associated with MACE”
HumansAtrial fibrillation undergoing index pulmonary vein isolationMedian follow-up of 30 monthsBothsn = 2,273
ESC Congress 2026 abstract
Cardiomyopathy
downin humans1
1 study
Cardiomyopathy
downin humans1
Cardiomyopathy is associated with left ventricular ejection fraction in humans (Patients with acute heart failure; compared with other etiologic groups) (LVEF 34%).
“patients with cardiomyopathy had the lowest LVEF (34%) compared to other groups (p<0.001).”
HumansPatients with acute heart failure; compared with other etiologic groupsheart
ESC Congress 2026 abstract
PEP/ET ratio
downin humans1
1 study
PEP/ET ratio
downin humans1
PEP/ET ratio is associated with left ventricular ejection fraction in humans (At least one cardiovascular risk factor; PEP/ET ≥0.425 versus <0.425) (57.0 ± 12.1 vs. 66.3 ± 9.6%; p<0.001).
“LVEF was significantly lower in the high-PEP/ET group than in the low-PEP/ET group (57.0 ± 12.1 vs. 66.3 ± 9.6%, p<0.001).”
HumansAt least one cardiovascular risk factor; PEP/ET ≥0.425 versus <0.425heartn = 415
A heart timing marker is linked to higher heart failure risk
ESC Congress 2026 abstract
Pulse wave velocity
downin humans1
1 study
Pulse wave velocity
downin humans1
Pulse wave velocity is associated with left ventricular ejection fraction in lymphoma patients receiving anthracycline-based chemotherapy (-2.7%, 95% CI -4.65 to -0.81).
“A ≥1 SD increase in PWV was associated with a mean LVEF decline of 2.7% (95% CI -4.65 to -0.81, p=0.006).”
Human trialin lymphoma patients receiving anthracycline-based chemotherapyn = 152
Atorvastatin and Pulse Wave Velocity in Anthracycline-based Chemotherapy
AHA Scientific Sessions 2025 abstract
Cardiac resynchronization therapy
upin humans1
1 study
Cardiac resynchronization therapy
upin humans1
Cardiac resynchronization therapy is associated with left ventricular ejection fraction in humans (heart failure) (35±8 vs. 28±5%).
“CRT was associated with the improvement of LVEF (35±8 vs. 28±5%, p<0.001)”
Human trialheart failureheart6 months80% mensn = 54
Cardiac resynchronization therapy improves functional status and cognition
International journal of cardiology
All 44Fewer
Funding
1 grant since 2020Japan Society for the Promotion of Science¥3.8M